Orthocell Gets Approval To Sell Remplir To The U.S. Department Of Defence Hospital Network

Orthocell’s Remplir nerve repair device has been approved for use across 51 U.S. Department of Defense and 170 Veterans Affairs hospital networks. The expanded access meaningfully broadens the company’s U.S. commercialization footprint and could support adoption in institutional healthcare channels. The news is positive for Orthocell but is likely to be a modest stock driver rather than a sector-wide catalyst.

Analysis

Orthocell’s Remplir nerve repair device has been approved for use across 51 U.S. Department of Defense and 170 Veterans Affairs hospital networks. The expanded access meaningfully broadens the company’s U.S. commercialization footprint and could support adoption in institutional healthcare channels. The news is positive for Orthocell but is likely to be a modest stock driver rather than a sector-wide catalyst.